310 related articles for article (PubMed ID: 16932282)
1. Do glucocorticoids affect outcome in Graves' disease following radioiodine therapy?
Salvatore D; Fenzi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):194-5. PubMed ID: 16932282
[No Abstract] [Full Text] [Related]
2. Endocrine ophthalmopathy and radioiodine therapy.
Karlsson FA
Acta Oncol; 2006; 45(8):1046-50. PubMed ID: 17118837
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease.
Hautzel H; Pisar E; Yazdan-Doust N; Schott M; Beu M; Müller HW
J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788
[TBL] [Abstract][Full Text] [Related]
4. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
5. Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe.
Rosetti S; Tanda ML; Veronesi G; Masiello E; Premoli P; Gallo D; Cusini C; Donati S; Sabatino J; Ippolito S; Piantanida E; Bartalena L
J Endocrinol Invest; 2020 Mar; 43(3):381-383. PubMed ID: 31587179
[No Abstract] [Full Text] [Related]
6. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid therapy of Graves' ophthalmopathy.
Bartalena L; Marocci C; Bogazzi F; Bruno-Bossio G; Pinchera A
Exp Clin Endocrinol; 1991 May; 97(2-3):320-7. PubMed ID: 1915650
[No Abstract] [Full Text] [Related]
8. Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease.
Jensen BE; Bonnema SJ; Hegedüs L
Eur J Endocrinol; 2005 Jul; 153(1):15-21. PubMed ID: 15994741
[TBL] [Abstract][Full Text] [Related]
9. Clinical practice. Graves' ophthalmopathy.
Bartalena L; Tanda ML
N Engl J Med; 2009 Mar; 360(10):994-1001. PubMed ID: 19264688
[No Abstract] [Full Text] [Related]
10. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine-Associated Exacerbation of Graves' Orbitopathy in the Japanese Population: Randomized Prospective Study.
Watanabe N; Noh JY; Kozaki A; Iwaku K; Sekiya K; Kosuga Y; Matsumoto M; Suzuki M; Yoshihara A; Ohye H; Kobayashi S; Kunii Y; Mukasa K; Sugino K; Inoue T; Ito K
J Clin Endocrinol Metab; 2015 Jul; 100(7):2700-8. PubMed ID: 25965082
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy and thyroid-associated orbitopathy: risk factors and preventive effects of glucocorticoids.
Dietlein M; Dederichs B; Weigand A; Schicha H
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 5():S190-4. PubMed ID: 10614920
[TBL] [Abstract][Full Text] [Related]
13. Thyroid associated orbitopathy--medication, radioiodine or operation?
Czarnywojtek A; Zgorzalewicz-Stachowiak M; Stangierski A; Florek E; Zdanowska J; Katarzyna H; Andrzejewska M; Ruchała M
Przegl Lek; 2012; 69(10):1140-3. PubMed ID: 23421110
[TBL] [Abstract][Full Text] [Related]
14. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy of Graves' hyperthyroidism in patients without pre-existing ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy?
Dederichs B; Dietlein M; Jenniches-Kloth B; Schmidt M; Theissen P; Moka D; Schicha H
Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):366-70. PubMed ID: 16915539
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association.
Lazarus JH; Bartalena L; Marcocci C; Kahaly GJ; Krassas G; Wiersinga WM;
J Endocrinol Invest; 2010 Jun; 33(6):409-13. PubMed ID: 20101098
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Four Treatments in Patients with Graves' Disease: a Network Meta-analysis.
Ren Z; Qin L; Wang JQ; Li Y; Li J; Zhang RG
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):317-22. PubMed ID: 25988881
[TBL] [Abstract][Full Text] [Related]
18. [Treatment with iodine radioisotopes and thyroid-associated ophthalmopathy in Graves' disease].
Rasmussen AK; Feldt-Rasmussen UF
Ugeskr Laeger; 1999 Oct; 161(43):5933-4. PubMed ID: 10778332
[No Abstract] [Full Text] [Related]
19. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism.
Bartalena L; Tanda ML; Piantanida E; Lai A
Eur J Endocrinol; 2005 Jul; 153(1):13-4. PubMed ID: 15994740
[No Abstract] [Full Text] [Related]
[Next] [New Search]
